, Volume 17, Issue 4, pp 319–324

The Importance of Achieving Additional Drug Benefits at a Reasonable Cost

A Review of the Fluoxetine Years
  • Nick Freemantle
  • James Mason
Current Opinion


Fluoxetine continues to be remarkably successful; greater volumes of this drug are sold than for any other antidepressant in the world. Prozac® has also become a household name. In this article we examine the circumstances that surround this success, and the evidence base that supports it. Rather than being a major step forward in the treatment for depression, the evidence for fluoxetine and for the selective serotonin reuptake inhibitors in general suggest at best a modest improvement in tolerability, with no evidence of improved efficacy. We note that the road to successwas not problem free for fluoxetine, and highlight the response of the sponsor in the development of subsequent drugs for CNS disorders.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fundholding [advertisement]. 1996; 5 (9)Google Scholar
  2. 2.
    SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302CrossRefGoogle Scholar
  3. 3.
    Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10PubMedCrossRefGoogle Scholar
  4. 4.
    Freemantle N. Are health decisions taken by health care professionals rational?Anon systematic review of experimental and quasi experimental literature. Health Policy 1996; 38: 71–81PubMedCrossRefGoogle Scholar
  5. 5.
    Mair FS, Carowley TS, Bundred PE. Prevalence, aetiology and management of heart failure in general practice. Br J Gen Pract 1996; 46: 77–9PubMedCentralPubMedGoogle Scholar
  6. 6.
    Clark KW, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J 1994; 71: 584–7CrossRefGoogle Scholar
  7. 7.
    Freemantle N. Cost effectiveness of non steroidal anti inflammatory drugs: what makes a NSAID good value for money? Rheumatology. In pressGoogle Scholar
  8. 8.
    Tatsumi M, Groshan K, Blakely, R et al. Pharmacological profile of antidepressants and related compounds at human monamine transporters. Eur J Pharmacol 1997; 340: 249–58PubMedCrossRefGoogle Scholar
  9. 9.
    Eccles M, Clarke J, Livingstone M, et al. North of England evidence based guidelines development project: guideline for the primary care management of dementia. BMJ 1998b; 317: 802–8PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptaker inhibitors compared with tricyclic antidepressants: a meta analysis. BMJ 1995; 310: 1433–8PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Eccles M, Freemantle N, Mason JM, for the North of England Guidelines Development Group. The choice of antidepressants for depression in primary care. Fam Pract 1999; 16: 103–11PubMedCrossRefGoogle Scholar
  12. 12.
    Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993; 306: 683–7PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta analysis. BMJ 1995; 310: 1433–8PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Eccles M, Freemantle N, Mason J. The choice of antidepressants for depression in primary care. Newcastle upon Tyne: Centre for Health Services Research, 1998Google Scholar
  15. 15.
    Eeeles M, Freemantle N, Mason JM. Mehtods of developing guidelines for efficient drug use in primary care: North of England Evidence Based Guidelines Development Project. BMJ 1998; 316: 1232–5CrossRefGoogle Scholar
  16. 16.
    Simon GE, Vonkorff M, Heilingenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996; 275: 1897–902PubMedCrossRefGoogle Scholar
  17. 17.
    Freemantle N, Drummond MF. Should clinical trials with concurrent economic analyses be blinded? JAMA 1997; 277: 63–4PubMedCrossRefGoogle Scholar
  18. 18.
    Beasley Jr CM, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991; 303: 685–92PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Fundholding [advertisement]. 1994; 3 (3)Google Scholar
  20. 20.
    Effective Health Care. The treatment of depression in primary care, Bulletin No. 5. Leeds: University of Leeds, 1993Google Scholar
  21. 21.
    Mason J, Freemantle N, Young P. The effect of the distribution of Effective Health Care Bulletins on prescribing selective serotonin reuptake inhibitors in primary care. Health Trends 1998/9: 120–2Google Scholar
  22. 22.
    Cowley G, Springen K, Leonard EA, et al. The promise of Prozac. Newsweek 1990; Mar 26: 42–5Google Scholar
  23. 23.
    Brown ED, Epperson SE. The personality pill. Time 1993; Oct 11: 59–60Google Scholar
  24. 24.
    Grilli R, Freemantle N, Minozzi S, et al. Impact of mass media on health services utilisation (Cochrane review). Oxford: The Cochrane Library, 1998: issue 3. Update softwareGoogle Scholar
  25. 25.
    Kramer PD. Listening to prozac: a psychiatrist explores antidepressant drugs and the remaking of the self. New York: Viking, 1993: xviGoogle Scholar
  26. 26.
    Wurtzel E. Prozac nation: young and depressed in America. New York: Riverhead, 1995. 302Google Scholar
  27. 27.
    Freemantle N. Does the UK need a fourth hurdle for pharmaceutical reimbursement to encourage the more cost effective prescribing of pharmaceuticals? Health Policy 1999; 46: 255–65PubMedCrossRefGoogle Scholar
  28. 28.
    Bland JM, Jones DR, Bennett S, et al. Is the clinical trial evidence about new drugs statistically adequate? Br J Clin Pharmacol 1985; 19: 155–60PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Smith PC. an economic perspective: Reforming markets in health care. Buckingham: Open University Press, 2000: 211–45Google Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Nick Freemantle
    • 1
  • James Mason
    • 1
  1. 1.Medicines Evaluation Group, Centre for Health EconomicsUniversity of YorkHeslington, YorkEngland

Personalised recommendations